Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-201 in Severe COVID-19
NCT04733833Phase 2Completed
- Sponsor
- VBL Therapeutics
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VB-201 in coronavirus disease 2019 (COVID-19), sponsored by VBL Therapeutics. Started Jan 2021; status: completed.
02
Drugs
VB-201
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04733833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04733833.